Figure 4
Figure 4. Assessment and genotyping analysis of B/M/NK individual clones derived from PMF-purified CD34+CD38−. Analysis of the progeny of single CD34+CD38− cell from PMF blood cells. Myeloid cells correspond to CD15+ cells; B cells, to CD19+ cells; and NK cells, to CD56+ cells. (A) Genotype analysis of single CD34+CD38− cell culture–derived clones from 2 PMF patients with respect to their monopotent B, NK, myeloid (M), bipotent B/M, B/NK, M/NK, or tripotent B/NK/M immunophenotypic characterization (clone type). (B) Immunophenotypic analysis of B/NK/myeloid clones from this PMF patient. The isotype control scattergrams are shown in the upper panel. The B, NK, and myeloid potentials were assessed by the presence of CD19+, CD56+, and CD15+cells, respectively, after 5 weeks of B, NK, and myeloid differentiation culture condition. The sequence traces of the PMF tripotent clone (MPL 1544 G>T [top] and MPL 1543 TG>AA [bottom]). Red arrows indicate the presence of a mutant peak.

Assessment and genotyping analysis of B/M/NK individual clones derived from PMF-purified CD34+CD38. Analysis of the progeny of single CD34+CD38 cell from PMF blood cells. Myeloid cells correspond to CD15+ cells; B cells, to CD19+ cells; and NK cells, to CD56+ cells. (A) Genotype analysis of single CD34+CD38 cell culture–derived clones from 2 PMF patients with respect to their monopotent B, NK, myeloid (M), bipotent B/M, B/NK, M/NK, or tripotent B/NK/M immunophenotypic characterization (clone type). (B) Immunophenotypic analysis of B/NK/myeloid clones from this PMF patient. The isotype control scattergrams are shown in the upper panel. The B, NK, and myeloid potentials were assessed by the presence of CD19+, CD56+, and CD15+cells, respectively, after 5 weeks of B, NK, and myeloid differentiation culture condition. The sequence traces of the PMF tripotent clone (MPL 1544 G>T [top] and MPL 1543 TG>AA [bottom]). Red arrows indicate the presence of a mutant peak.

Close Modal

or Create an Account

Close Modal
Close Modal